SCNI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Scinai Immunotherapeutics Ltd (SCNI) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The lack of positive financial performance, no recent news or catalysts, and neutral trading sentiment make it unsuitable for immediate investment. A hold position is recommended until more favorable conditions arise.
The MACD is positive and expanding, indicating a slight bullish momentum. However, the RSI is neutral at 49.438, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is currently trading below the pivot level of 0.6, with key support at 0.572 and resistance at 0.627. Overall, the technical indicators suggest no strong entry point.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
The stock is down -2.37% in pre-market trading. Financial performance shows a decline in net income (-4.29% YoY) and EPS (-100% YoY). There is no recent congress trading data or analyst upgrades.
In Q4 2024, revenue remained flat at 206,000 (0.00% YoY). Net income dropped to -2,230,000 (-4.29% YoY), and EPS fell by 100% YoY to 0. Gross margin remains negative at -202.29%. The company is not showing signs of financial growth.
No analyst rating or price target data is available for SCNI.
